SALLIE WEART

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease.

Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases.

Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.

Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.

Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.

Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.

Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease. The Boxing Therapy for Parkinsons Access Act (H.R. 9150), including advocacy related to requiring the VA to furnish boxing-based exercise classes to veterans who are enrolled in the VA health care system, have been diagnosed with ""Parkinson's disease or a similar movement disorder"", and specifically elect to participate in such classes.

Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease. The Boxing Therapy for Parkinsons Access Act (H.R. 9150), including advocacy related to requiring the VA to furnish boxing-based exercise classes to veterans who are enrolled in the VA health care system, have been diagnosed with ""Parkinson's disease or a similar movement disorder"", and specifically elect to participate in such classes.

Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.

Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.

Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.

Lobbying to ban the use of known environmental risk factors of Parkinsons disease, including Trichloroethylene (TCE) and paraquat, in the United States. S.J.Res.19/H.J.Res.27/ H.J.Res.34 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)" The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease.

Lobbying to ban the use of or reduce exposures to environmental health threats linked to Parkinsons disease, including Trichloroethylene (TCE) and paraquat, in the United States. S.J.Res.19/H.J.Res.27/ H.J.Res.34 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to """Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)""" The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease.

Lobbying to ban the use of or reduce exposures to environmental health threats linked to Parkinsons disease, including Trichloroethylene (TCE) and paraquat, in the United States. S.J.Res.19/H.J.Res.27/ H.J.Res.34 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to """Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)""" The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease.

Lobbying to ban the use of known environmental risk factors of Parkinsons disease, including Trichloroethylene (TCE) and paraquat, in the United States. S.J.Res.19/H.J.Res.27/ H.J.Res.34 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)" The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease.

S.925/H.R.2036 - Credit for Caring Act of 2025: seeks to amend the Internal Revenue Code of 1986 to provide a nonrefundable credit for working family caregivers.

Lobbying to increase the affordability and accessibility of treatments for Parkinsons disease. S.1227/H.R.2491- Alleviating Barriers for Caregivers (ABC) Act: requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits.

Funding for implementation of Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). S.2587/H.R.5304 - Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the National Neurological Conditions Surveillance System under the Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. S.2572/H.R.4016 - Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP) within the FY 2026 Defense Appropriation bills. H.R.3944 - Funding for the Parkinson's Disease Research, Education and Clinical Centers under the Department of Veterans Affairs within the FY 2026 Military Construction, Veterans Affairs and Related Agencies Appropriation bills. Federal Funding for Parkinson's Disease research in upcoming Fiscal Year 2027 appropriations bills, including support for the National Institute of Neurological Disorders and Stroke's Morris K. Udall Centers of Excellence Program.

Funding for implementation of Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). S.2587/H.R.5304 - Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the National Neurological Conditions Surveillance System under the Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. S.2572/H.R.4016 - Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP) within the FY 2026 Defense Appropriation bills. H.R.3944 - Funding for the Parkinsons Disease Research, Education and Clinical Centers under the Department of Veterans Affairs within the FY 2026 Military Construction, Veterans Affairs and Related Agencies Appropriation bills.

Funding for implementation of Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). S.2587/H.R.5304 - Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the National Neurological Conditions Surveillance System under the Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. S.2572/H.R.4016 - Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP) within the FY 2026 Defense Appropriation bills. H.R.3944 - Funding for the Parkinson's Disease Research, Education and Clinical Centers under the Department of Veterans Affairs within the FY 2026 Military Construction, Veterans Affairs and Related Agencies Appropriation bills. Federal Funding for Parkinson's Disease research in upcoming Fiscal Year 2027 appropriations bills, including support for the National Institute of Neurological Disorders and Stroke's Morris K. Udall Centers of Excellence Program.

Funding for implementation of Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). S.2587/H.R.5304 - Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the National Neurological Conditions Surveillance System under the Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. S.2572/H.R.4016 - Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP) within the FY 2026 Defense Appropriation bills. H.R.3944 - Funding for the Parkinsons Disease Research, Education and Clinical Centers under the Department of Veterans Affairs within the FY 2026 Military Construction, Veterans Affairs and Related Agencies Appropriation bills.

Funding for implementation of Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). S.2587/H.R.5304 - Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the National Neurological Conditions Surveillance System under the Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. S.2572/H.R.4016 - Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP) within the FY 2026 Defense Appropriation bills. H.R.3944 - Funding for the Parkinsons Disease Research, Education and Clinical Centers under the Department of Veterans Affairs within the FY 2026 Military Construction, Veterans Affairs and Related Agencies Appropriation bills.

Funding for implementation of Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). S.2587/H.R.5304 - Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the National Neurological Conditions Surveillance System under the Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. S.2572/H.R.4016 - Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP) within the FY 2026 Defense Appropriation bills. H.R.3944 - Funding for the Parkinson's Disease Research, Education and Clinical Centers under the Department of Veterans Affairs within the FY 2026 Military Construction, Veterans Affairs and Related Agencies Appropriation bills. Federal Funding for Parkinson's Disease research in upcoming Fiscal Year 2027 appropriations bills, including support for the National Institute of Neurological Disorders and Stroke's Morris K. Udall Centers of Excellence Program.

Lobbying to increase the affordability and accessibility of treatments for Parkinsons disease. S.1227/H.R.2491- Alleviating Barriers for Caregivers (ABC) Act: requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits.

Funding for implementation of Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). S.2587/H.R.5304 - Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the National Neurological Conditions Surveillance System under the Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. S.2572/H.R.4016 - Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP) within the FY 2026 Defense Appropriation bills. H.R.3944 - Funding for the Parkinson's Disease Research, Education and Clinical Centers under the Department of Veterans Affairs within the FY 2026 Military Construction, Veterans Affairs and Related Agencies Appropriation bills. Federal Funding for Parkinson's Disease research in upcoming Fiscal Year 2027 appropriations bills, including support for the National Institute of Neurological Disorders and Stroke's Morris K. Udall Centers of Excellence Program.

Funding for implementation of Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). S.2587/H.R.5304 - Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the National Neurological Conditions Surveillance System under the Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. S.2572/H.R.4016 - Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP) within the FY 2026 Defense Appropriation bills. H.R.3944 - Funding for the Parkinsons Disease Research, Education and Clinical Centers under the Department of Veterans Affairs within the FY 2026 Military Construction, Veterans Affairs and Related Agencies Appropriation bills.

Funding for implementation of Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). S.2587/H.R.5304 - Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the National Neurological Conditions Surveillance System under the Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. S.2572/H.R.4016 - Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP) within the FY 2026 Defense Appropriation bills. H.R.3944 - Funding for the Parkinsons Disease Research, Education and Clinical Centers under the Department of Veterans Affairs within the FY 2026 Military Construction, Veterans Affairs and Related Agencies Appropriation bills.

Funding for implementation of Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). S.2587/H.R.5304 - Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the National Neurological Conditions Surveillance System under the Centers for Disease Control and Prevention within the FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. S.2572/H.R.4016 - Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP) within the FY 2026 Defense Appropriation bills. H.R.3944 - Funding for the Parkinson's Disease Research, Education and Clinical Centers under the Department of Veterans Affairs within the FY 2026 Military Construction, Veterans Affairs and Related Agencies Appropriation bills. Federal Funding for Parkinson's Disease research in upcoming Fiscal Year 2027 appropriations bills, including support for the National Institute of Neurological Disorders and Stroke's Morris K. Udall Centers of Excellence Program.

S.925/H.R.2036 - Credit for Caring Act of 2025: seeks to amend the Internal Revenue Code of 1986 to provide a nonrefundable credit for working family caregivers.

Lobbying to ban the use of known environmental risk factors of Parkinsons disease, including Trichloroethylene (TCE) and paraquat, in the United States. S.J.Res.19/H.J.Res.27/ H.J.Res.34 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)" The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease.

Lobbying to ban the use of or reduce exposures to environmental health threats linked to Parkinsons disease, including Trichloroethylene (TCE) and paraquat, in the United States. S.J.Res.19/H.J.Res.27/ H.J.Res.34 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to """Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)""" The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.

FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced). H.R.9233: The HEALTHY BRAINS Act - developing support for implementation funding for centers of excellence within NIH.

FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced).

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.4366/S.2127 - FY24 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. FY24 (H.R.4365/S.2587) and FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.

FY 2024 Appropriations bills including funding requests for Parkinson's research at: H.R.4365/S.2587 - The Department of Defense within the FY 2024 Defense Appropriation bill. H.R.5894/S.2624 - The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. H.R.4368/S.2131 - The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.4366/S.2127 - The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Increased funding for NIEHS (no bill introduced). Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP).

H.R.4366/S.2127 - FY24 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. FY24 (H.R.4365/S.2587) and FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.

FY 2024 Appropriations bills including funding requests for Parkinson's research at: H.R.4365/S.2587 - The Department of Defense within the FY 2024 Defense Appropriation bill. H.R.5894/S.2624 - The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. H.R.4368/S.2131 - The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.4366/S.2127 - The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Increased funding for NIEHS (no bill introduced). Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP).

FY 2024 Appropriations bills including funding requests for Parkinson's research at: H.R.4365/S.2587 - The Department of Defense within the FY 2024 Defense Appropriation bill. H.R.5894/S.2624 - The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. H.R.4368/S.2131 - The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.4366/S.2127 - The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Increased funding for NIEHS (no bill introduced). Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP).

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

General education on the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. H.R.8774/ S.4921: FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 - The Elizabeth Dole Home Care Act: Increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. H.R.8580 / S.4677 - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill: Supports increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.

FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. FY24 and FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 -The Elizabeth Dole Home Care Act- increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. H.R. 8580 / Senate bill not filed - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. H.R. 8774/ Senate bill not yet filed - FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.

General education on the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. H.R.8774/ S.4921: FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 - The Elizabeth Dole Home Care Act: Increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. H.R.8580 / S.4677 - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill: Supports increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.

FY 2024 Appropriations bills including funding requests for Parkinson's research at: H.R.4365/S.2587 - The Department of Defense within the FY 2024 Defense Appropriation bill. H.R.5894/S.2624 - The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. H.R.4368/S.2131 - The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.4366/S.2127 - The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Increased funding for NIEHS (no bill introduced). Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP).

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.